POU5F1 (OCT3/4) identifies cells with pluripotent potential in human germ cell tumors.
Human germ cell tumors (GCTs) may have variable histology and clinical behavior, depending on factors such as sex of the patient, age at clinical diagnosis, and anatomical site of the tumor. Some types of GCT, i.e., the seminomas/germinomas/dysgerminomas and embryonal carcinomas (the stem cell component of nonseminomas), have pluripotent potential, which is demonstrated by their capacity to differentiate into somatic and/or extraembryonic elements. Although embryonal carcinoma cells are intrinsically pluripotent, seminoma/germinoma/dysgerminoma cells, as well as their precursor carcinoma in situ/gonadoblastoma cells, have the phenotype of early germ cells that can be activated to pluripotency. The other types of GCT (teratomas and yolk sac tumors of infants and newborn, dermoid cyst of the ovary, and spermatocytic seminoma of elderly) are composed of (fully) differentiated tissues and lack the appearance of undifferentiated and pluripotent stem cells. OCT3/4, a transcription factor also known as OTF3 and POU5F1, is involved in regulation of pluripotency during normal development and is detectable in embryonic stem and germ cells. We analyzed the presence of POU5F1 in GCT and other tumor types using immunohistochemistry. The protein was consistently detected in carcinoma in situ/gonadoblastoma, seminomas/germinoma/dysgerminoma, and embryonal carcinoma but not in the various types of differentiated nonseminomas. Multitumor tissue microarray analysis covering >100 different tumor categories and 3600 individual cancers verified that POU5F1 expression is specific for particular subtypes of GCT of adults. No protein was observed in GCT of newborn and infants, spermatocytic seminomas, and the various tumors of nongerm cell origin. In addition, no difference in staining pattern was found in chemosensitive and chemoresistant GCT of adults. These results indicate preservation of the link between POU5F1 and pluripotency, as reported during normal development, after malignant transformation. Therefore, POU5F1 immunohistochemistry is an informative diagnostic tool for pluripotent GCT and offers new insights into the histological heterogeneity of this cancer.
Looijenga
Leendert H J
LH
Pathology/Lab. for Exp. Patho-Oncology, Josephine Nefkens Institute, Rotterdam, The Netherlands. L.Looijenga@erasmusmc.nl
Stoop
Hans
H
de Leeuw
Hubert P J C
HP
de Gouveia Brazao
Carlos A
CA
Gillis
Ad J M
AJ
van Roozendaal
Kees E P
KE
van Zoelen
Everardus J J
EJ
Weber
Rob F A
RF
Wolffenbuttel
Katja P
KP
van Dekken
Herman
H
Honecker
Friedemann
F
Bokemeyer
Carsten
C
Perlman
Elizabeth J
EJ
Schneider
Dominik T
DT
Kononen
Juha
J
Sauter
Guido
G
Oosterhuis
J Wolter
JW
D000293:Adolescent; D000328:Adult; D002648:Child; D004268:DNA-Binding Proteins / Q000096:biosynthesis* / Q000235:genetics; D005260:Female; D005854:Germ Cells / Q000378:metabolism; D006801:Humans; D007150:Immunohistochemistry; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D008875:Middle Aged; D009373:Neoplasms, Germ Cell and Embryonal / Q000378:metabolism* / Q000473:pathology*; D050814:Octamer Transcription Factor-3; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics; D013091:Spermatogenesis / Q000502:physiology; D014157:Transcription Factors / Q000096:biosynthesis* / Q000235:genetics
D004268:DNA-Binding Proteins; D050814:Octamer Transcription Factor-3; C494173:POU5F1 protein, human; D012333:RNA, Messenger; D014157:Transcription Factors